Please login to the form below

Not currently logged in
Email:
Password:

Dr Desiree Luthman joins Verona Pharma

She takes up its vice president position

Desiree LuthmanUK-based clinical stage biopharma company Verona Pharma has appointed Dr Desiree Luthman as its vice president of regulatory affairs.

Luthman’s expertise lies in a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing.

She has also held various regulatory positions for global pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene and AstraZeneca.

Jan-Anders Karlsson, chief executive officer of Verona Pharma, said: “We welcome Desiree to our growing pharma team.

“She has an accomplished track record of working closely with the FDA and EMA on behalf of international healthcare companies to achieve key regulatory milestones.

“Her vast experience will be instrumental as we advance our regulatory plans in the US and Europe under her leadership in our effort to deliver important new therapies to patients with respiratory diseases.”

Prior to her new role in Verona Pharma, Luthman previously directed regulatory activities related to pulmonary disease at Sanofi and led its regulatory team through the FDA approval of dupilumab for atopic dermatitis in the US.

27th June 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...